Surface Oncology Inc SURF:NASDAQ

Last Price$1.76NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/24/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.67 (2)
Ask (Size)$1.86 (2)
Day Low / HighN/A - N/A

Surface Oncology to Study Potential Antibody's Use For Treatment-Naive Hepatocellular Carcinoma

8:55AM ET 10/04/2021 MT Newswires
Surface Oncology (SURF) on Monday announced plans to start a randomized Phase 2 clinical study evaluating its SRF388 potential antibody against IL-27 in combination with Roche's atezolizumab and bevacizumab in patients with treatment-naive hepatocellular carcinoma.

The clinical-stage immuno-oncology company expects to dose the first patient in early 2022.

About 100 patients will be randomized to receive either SRF388 or a placebo in combination with atezolizumab and bevacizumab. Surface Oncology anticipates a futility analysis in early 2023 and final data in H1 2024, it said.

The company also said it has expanded its debt facility with K2 HealthVentures to $50 million and maintains a projected cash runway through 2023.

Price: 7.90, Change: 0.00, Percent Change: